SCHEMBL2008903

SCHEMBL2008903

Cc1c([C@@H](C)NC(=O)c2ccc3cc([C@@](C)(O)C(F)(F)F)ccc3c2)cnn1C

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.51
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP17A1 P05093 7/20 0.41
CYP3A4 P08684 6/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
PDE2A O00408 2/20 0.36
B3GNT2 Q9NY97 1/20 0.35
PTPN1 P18031 1/20 0.35
PPARG P37231 2/20 0.34
SLC8A1 P32418 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1839524 1.00 BRPF1 (0.51) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1841666 1.00 BRPF1 (0.51) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1839961 1.00 BRPF1 (0.51) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1839569 0.90 BRPF1 (0.54) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1843146 0.90 BRPF1 (0.54) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1838548 0.89 BRPF1 (0.55) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1841352 0.88 BRPF1 (0.49) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1838653 0.87 BRPF1 (0.51) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL1841353 0.87 BRPF1 (0.51) BRPF1MEN1PKMKMT2ASMN1; SMN2
SCHEMBL14217658 0.81 BRPF1 (0.54) BRPF1MEN1PKMKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964732-B2 Substituted bicyclocarboxyamide compounds PFIZER INC. (US) 2011-06-21 US disclosed
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds TRPV1, OPRL1, CNR1 BRPF1 1691/4885MEN1 4680/4885PKM 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.